SERB Pharmaceuticals has agreed to pay Hansa Biopharma €110 million upfront for European rights to a conditionally approved kidney transplant drug.
Tag Archive for: Hansa Biopharma AB
Dr. Edwin P. Ewing, Jr. - http://phil.cdc.gov/phil/home.asp ID#: 70 US Department of Health and Human ServicesInitial clinical data indicate that the recombinant cysteine protease imlifidase, developed by Hansa Biopharma AB, may significantly reduce levels of anti-AAV antibodies, potentially enabling adeno-associated virus (AAV)-based gene therapies in patients previously deemed ineligible due to pre-existing immunity.